Bioclassifier has licensed to NanoString the rights to develop in vitro diagnostic and research products based on the so-called PAM50 gene signature and NanoString's nCounter platform. Meantime, ARUP Laboratories will next month launch a laboratory-developed qPCR test based on the signature.
Using a variety of genetic approaches, University of North Carolina at Chapel Hill researchers have shown that some SNPs previously linked to atherosclerosis risk can affect the splicing of a long, non-coding RNA that's found in both circular and linear forms in human cells.
"We often try to have these heroic 50,000-patient studies out there. Really, a little bit of biological plausibility is all that is needed," said Howard McLeod, head of the Pharmacogenetics in Every Nation Initiative.
